Concepedia

S. Qin

SQ

3

Publications

322

Citations

3

H-Index

2011

Active since

Affiliations

Samsung Medical Center(Current)

S. Qin is an author at Samsung Medical Center specializing in radiation oncology, pharmacotherapy, and hepatology.

ORCID

Top concepts

Publications per year

2011–2019

3

Publications

3

IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

Ann‐Lii Cheng, S. Qin, Masafumi Ikeda et al. · Annals of Oncology · 2019 · 191 citations

, , +10

Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).

Ann‐Lii Cheng, Yubin Kang, J. Park et al. · Journal of Clinical Oncology · 2011 · 119 citations

Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment

Jordi Bruix, Philippe Merle, Alessandro Granito et al. · Journal of Hepatology · 2017 · 12 citations

, , +10

Rows per page

1–3 of 3